• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Urine test to evaluate immunotherapy success gets $1.8 million NIH research grant

Bioengineer by Bioengineer
April 3, 2019
in Chemistry
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Georgia Tech / EllaMaru Studios work for hire / press handout

New immunotherapies can dramatically defeat cancer. But more often, cancer evades them, and doctors need to know quickly when that happens, so they can adjust treatment. An experimental urine test to detect immunotherapy effectiveness very early has received a major funding boost.

The National Institutes of Health has granted $1.8 million to a research project at the Georgia Institute of Technology, where the lab of Gabe Kwong has already established a platform to detect complex disease and immune activity. Kwong will use the new funding from the NIH’s National Cancer Institute to advance the platform to evaluate immunotherapy progress.

The platform uses an intravenous injection of “activity sensors,” nanoparticles that detect early enzyme activity of immune cells attacking cancer. The sensor confirms the attack with a fluorescent signal in the urine.

Shifty resistance

Cancer’s defenses are crafty and can thwart treatment from the start or disrupt initially successful treatment later on, so progress must be continually monitored, which Kwong’s lab is engineering the particle to do. Early resistance to therapy looks very different from later resistance.

“We need to be able to classify different forms of resistance, so we can combat them better,” said Kwong, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.

He plans to adapt the sensing technology to profile those subtleties. It is already engineered to have advantages over other tests that have recently entered the market, which look for signals that come later, such as dead cancer cells shedding their DNA into the bloodstream.

“These tests can be quite effective, but some issues limit them, particularly in early detection: You have five liters of blood. Whatever the cells shed gets diluted significantly in your bloodstream,” Kwong said.

That makes these signals harder to detect in blood tests.

Enriched signals

“Our sensors’ signals get concentrated in the urine, so, not only are they not diluted in the blood, but we usually see a hundred- to thousandfold signal enrichment.”

Kwong’s lab has already developed the sensors, which are biocompatible nanoparticles, refined them as a reliable platform, and engineered variations that experimentally sense blood clots, liver fibrosis, organ transplant rejection, and cancer. Kwong has published multiple papers on activity sensor urine test successes.

Kwong’s endgame ambitions: “In five to ten years, we want to expand the platform to detect most all major complex diseases and progress in treating them.”

Q & A

What is the activity sensor and how does the urine test work?

The sensors are nanoscale balls with bristles made of short amino acid strands that have fluorescent “reporter” molecules attached to their tips. The sensors tend to accumulate in compromised tissue like cancer.

When immunotherapy — which can be engineered T cells or the body’s own T cells aided by medication — attack cancer cells, the T cells secrete an enzyme called granzyme that severs target amino acid strands in the cancer cells, triggering their death. The activity sensor’s bristles mimic those strands, so granzymes cut the bristles at the same time.

“That releases the reporter molecules, which are so small that they easily make it through the kidney’s filtration and go into the urine,” said Kwong who directs the Laboratory for Synthetic Immunity in the Coulter Department.

Then the urine turns a fluorescent color that can be analyzed to determine the intensity of the immunotherapy’s attack on cancer.

Is there a need for this kind of test?

“Many patients, especially those with solid tumors, are not responding to this treatment,” Kwong said. “The non-responders need to be detected very quickly.”

There are also diagnostic pitfalls the experimental sensor is devised to overcome: For example, a current measure of treatment success is tumor shrinkage, but when T cells initially cram into a tumor, it can swell. That sometimes leads doctors to believe that a therapy that is actually very effective is not working, and they may discontinue it.

“This test does not measure size; it measures activity,” Kwong. “If those swelling tumors are very high in granzyme activity, that’s a great sign, and we will be able to pick that up.”

How is the dream of detecting most known complex diseases even feasible?

Quite conveniently, the human genome produces “only” 550 proteases, a particular type of enzyme relevant to detecting and combating disease. Kwong believes researchers can adapt this platform to detect any of them and that there’s a need for that.

“Granzymes are also activated by other things like an infection, so detecting granzyme alone risks getting interference when you’re looking at cancer treatment effectiveness. We’re developing a panel of sensors that gives us the specificity of T cell activity in tumors over the possible activity of T cells fighting, say, a cold,” Kwong said.

“We want to build 550 different protease-detecting probes, and depending on what disease you have, they would expose a profile of the proteases in varying ratios.”

The probes could be combined into a cocktail to detect budding cancer, immunotherapy effectiveness or infections, and machine learning would analyze their respective fingerprints in the urine signals.

The grant was provided by the National Cancer Institute at the National Institutes of Health. The grant number is 1 R01 CA237210-01. The content is the sole responsibility of the authors and does not necessarily represent official views of the National Institutes of Health.

###

Media Contact
Ben Brumfield
[email protected]

Original Source

http://www.rh.gatech.edu/news/619978/urine-test-evaluate-immunotherapy-success-gets-18-million-nih-research-grant

Tags: Biomedical/Environmental/Chemical EngineeringBiotechnologyMedicine/HealthNanotechnology/MicromachinesPharmaceutical SciencesTechnology/Engineering/Computer Science
Share12Tweet8Share2ShareShareShare2

Related Posts

5 Innovations Securing Water Sources and Ensuring Availability

5 Innovations Securing Water Sources and Ensuring Availability

August 1, 2025
blank

Innovative Imaging Technique Reveals Elemental Distributions in Frozen Solvents within Nanomaterials

August 1, 2025

Innovative Advances in 2.5D MOF Materials Using Triptycene Derivatives

August 1, 2025

HKU Researchers Illuminate the Impact of Urban Light Pollution

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Sustainability Accelerator Chooses 41 Promising Projects Poised for Rapid Scale-Up

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Melanthiaceae Genomes Reveal Giant Genome Evolution Secrets

Tracking Tumor DNA During Gastric Cancer Treatment

Heparan Sulfate Protein Improves MPS IIIB Symptoms

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.